Lenalidomide: A review of its use in the treatment of relapsed or refractory multiple myeloma

Drugs

Volumn 71, Issue 5, 2011, Pages 625-649

  Scott, Lesley J ^a   Lyseng Williamson, Katherine A ^a   Iida, S ^b   Palumbo, A ^c   Uaprasert, N ^d   Wang, M ^e   Zangari, M ^f   Zhang, L ^e  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF TURIN   (Italy)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

Author keywords

Adis Drug Evaluations; Lenalidomide; Multiple myeloma

Indexed keywords

ACETYLSALICYLIC ACID; BASIC FIBROBLAST GROWTH FACTOR; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; GAMMA INTERFERON; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; WARFARIN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE DESTRUCTION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME DISORDER; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HEALTH SERVICE; HUMAN; HYPERGLYCEMIA; HYPESTHESIA; HYPOKALEMIA; HYPOTENSION; IMMUNOMODULATION; KIDNEY DISEASE; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE;

EID: 79953238852     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206420-000000000-00000     Document Type: Article

References (89)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. 2002. CA Cancer J Clin 2005; 55 (2): 74-108.
2. Haubitz M, Peest D. Myeloma: new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 2006; 21: 582-90. (Pubitemid 43372902)
3. Altieri A, Chen B, Bermejo JL, et al. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 2006; 42: 1661-70. (Pubitemid 44118762)
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): multiple myeloma version 1.2011 [online]. Available from URL http://www.nccn.org/professionals/physician-gls/PDF/mye loma.pdf [Accessed 2010 Oct 9].
5. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging towarda bright future. CACancerJClin 2007; 57(5): 301-18. (Pubitemid 47620125)
6. Harousseau J-L, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360 (25): 2645-54.
7. Harousseau J-L, Dreyling M. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl. 5: v155-7.
8. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006; 42 (11): 1612-22. (Pubitemid 44118763)
9. Cook G, Campbell JDM. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev 1999; 13: 115-62.
10. Bernal M, Garrido P, Jimenez P, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol 2009; 70: 854-7.
11. Quach H, Ritchie D, Stewart AK, et al. Mechanisms of ac- tion of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32.
12. Brenne A-T, Fagerli U-M, Shaughnessy JD, et al. Higher expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol 2009; 82: 354-63.
13. Jourdan M, Tarte K, Legouffe E, et al. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999; 10: 65-70. (Pubitemid 29158740)
14. Colucci S, Brunetti G, Mori G, et al. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia 2009; 23: 2139-46.
15. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23 (9): 1545-56.
16. Dimopoulos MA, Kastritis E. The role of novel drugs in multiple myeloma. Ann Oncology 2008; 19 Suppl. 7: vii121-7.
17. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-77.
18. Ludwig H, Strasser-Weippi K, Schreder M, et al. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann Oncol 2007; 18 Suppl. 9: ix64-70.
19. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010; 24 Suppl. 1: S13-9.
20. Chanan-Khan AA, Cheson BD. Lenalidomide for the treat- ment of B-cell malignancies. J Clin Oncol 2008; 26 (9): 1544-52.
21. Reske T, Fulciniti M, Munshi NC. Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol 2010; 27 Suppl. 1: 7-13.
22. Li S, Gill N, Lentzsch S. Recent advances of IMiDs in cancer therapy. Curr Opin Oncol 2010; 22: 579-85.
23. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
24. Teo SK. Properties of thalidomide and its analogues: im- plications for anticancer therapy. AAPS J 2005; 7 (1): E14-9. (Pubitemid 41554303)
25. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177 (6): 1675-80. (Pubitemid 23146134)
26. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98 (1): 210-6.
27. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone- remodeling markers in multiple myeloma. Leukemia 2008; 22 (10): 1925-32.
28. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99 (12): 4525-30. (Pubitemid 34627223)
29. Dredge K, Marriott JB, Macdonald CD, et al. Novel tha- lidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87 (10): 1160-72.
30. Dredge K, Horsfall R, Robinson SP, et al. Orally adminis- tered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69 (1-2): 56-63. (Pubitemid 40410468)
31. Burington B, Barlogie B, Zhan F, et al. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 2008; 14 (15): 4821-9.
32. Gandhi AK, Kang J, Capone L, et al. Dexamethasone sy- nergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immuno-modulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10 (2): 155-67.
33. Avet-Loiseau H, Soulier J, Fermand JP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010; 24 (3): 623-8.
34. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009; 114 (3): 522-5.
35. Heider U, Fleissner C, Zavrski I, et al. Bone markers in multiple myeloma. Eur J Cancer 2006; 42: 1544-53. (Pubitemid 44118764)
36. Celgene Corporation. Revlimid® (lenalidomide) 5mg, 10 mg, 15mg and 25 mg capsules: US prescribing information [online]. Available from URL: http://www.revli mid.com/pdf/REVLIMID-PI.pdf [Accessed 2010 Aug 9].
37. European Medicines Agency. Summary of product character- istics: Revlimid® [online]. Available from URL: http://www. ema. europa.eu/docs/en-GB/doument-library/EPAR-Produ ct-Information/human/000717/ WC5000 56018.pdf [Accessed 2010 Sep 13].
38. Iida S, Chou T, Okamoto S, et al. Lenalidomide plus dexa- methasone treatment in Japanese patients with relapsed/refractory multiple myeloma [published erratum appears in Int J Hematol 2010; 92 (1): 127-8]. Int J Hematol 2010; 92 (1): 118-26.
39. Richardson PG, Schlossman RL, Weller E, et al. Immuno- modulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100 (9): 3063-7. (Pubitemid 35217050)
40. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenali- domide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47 (12): 1466-75. (Pubitemid 350115306)
41. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357 (21): 2133-42. (Pubitemid 350146108)
42. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357 (21): 2123-32. (Pubitemid 350146107)
43. Yong K, Alegre Amor A, Browne P, et al. A multicenter, single-arm, open-label safety and quality of life study of lenalidomide plus dexamethasone in previously treated patients with multiple myeloma [abstract no. 0944]. Hae-matologica 2010; 95 Suppl. 2: 392.
44. Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, et al. Safety, efficacy, and quality of life study of lenalidomide plus dexamethasone in previously treated patients with multiple myeloma: the Spanish experience [abstract no. 3045]. 52nd Annual Meeting and Exposition of the American Society of Hematology; 2010 Dec 4-7; Orlando (FL).
45. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT: European Group for Bone Marrow Transplant. Br J Haematol 1998; 102 (5): 1115-23. (Pubitemid 28435189)
46. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexametha-sone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23 (11): 2147-52.
47. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112 (12): 4445-51.
48. Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalido- mide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009; 82 (6): 426-32.
49. Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexametha-sone. J Clin Oncol 2010; 28 (1): 132-5.
50. Foa R, Weber D, Dimopoulos M, et al. Lenalidomide/dexamethasone improves response and prolongs time to progression, even in the patients with IgA multiple myeloma: a sub-analysis of the MM-009/010 studies [abstract no. 4839]. Blood 2007; 110 (11).
51. Delforge M, Facon T, Bravo M-L, et al. Lenalidomide plus dexamethasone has similar tolerability and efficacy in treatment of relapsed/refractory multiple myeloma patients with or without history of neuropathy [abstract no. 3873]. Blood 2009; 114 (22).
52. San Miguel J, Dimopoulos M, Bravo M-L, et al. Longer duration of treatment and maintenance of best response with lenalidomide +dexamethasone increases overall survival in patients with relapsed/refractory multiple myeloma [abstract no. 0949]. Haematologica 2009; 24 Suppl. 2: 382.
53. San Miguel JF, Dimopoulos M, Weber D, et al. Dexa- methasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenali domide/dexamethasone (MM009/010 sub-analysis) [abstract no. 2712]. Blood 2007; 110 (11): 796.
54. Plus poster presented at the 49th Annual Meeting and Exposition of the American Society of Hematology; 2007 Dec 8-11, Atlanta (GA).
55. Harousseau J-L, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010; 95 (10): 1738-44.
56. Stewart AK, Chang H, Trudel S, et al. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence of clonal evolution [letter]. Leukemia 2007; 21: 2358-9. (Pubitemid 350011711)
57. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treat- ment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cyto-genetic abnormalities and of previous therapies. Leukemia 2010; 24 (10): 1769-78.
58. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23 (10): 1716-30.
59. Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22 (8): 1485-93.
60. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 116 (16): 3807-14.
61. Dimopoulos MA, Christoulas D, Roussou M, et al. Lenali- domide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Hemat 2010; 85 (1): 1-5.
62. Klein U, Neuben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Annals Hematol 2011; 90 (4): 429-39.
63. Roig M, Ibanez A, Garcia I, et al. Activity and safety of lenalidomide and dexamethasone in multiple myeloma patients with advanced renal failure: a Spanish multicenter retrospective study [abstract no. 1886]. Blood 2009; 114 (22).
64. Chen C, Reece DE, Siegel D, et al. Expanded safety experi- ence with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146 (2): 164-70.
65. Ishak J, Dimopoulos MA, Weber D, et al. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone [abstract no. 3708]. Blood 2008; 112 (11).
66. Lonial S, Baz R, Swern AS, et al. Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone [abstract no. 2879]. Blood 2009; 114 (22).
67. Delforge M, Blau IW, Hernandez MT, et al. Post-Approval Safety Study (PASS) of lenalidomide compared with other treatments in patients with relapsed or refractory multiple myeloma: evaluation of peripheral neuropathy in the first 1011 patients [abstract no. 1939]. Blood 2010; 116 (21).
68. Deniz B, Ishak KJ, Shearer A, et al. Economic evaluation of lenalidomide use for multiple myeloma in Scotland in patients who have received one prior therapy [abstract no. PSY14]. Value Health 2008; 11 (3): A156.
69. Deniz HB, Ishak KJ, Edwards DR, et al. Economic evaluation of lenalidomide for the treatment of multiple myeloma in Wales in patients who have received at least one prior therapy [abstract no. 0804]. Haematologica 2008; 93 Suppl. 1: 320-1.
70. Deniz B, Morgan G, Schey S, et al. Economic evaluation of lenalidomide combined with dexamethasone for the treatment of multiple myeloma in the UK [abstract no. 2400]. Blood 2008; 112(11).
71. Scottish Medicines Consortium. Resubmission: lenalido- mide 5mg, 10mg, 15mg and 25mg capsules (Revlimid®): no. (441/08) [online]. Available from URL: http://www. scottishmedicines.org.uk/files/lenalidomide-Revlimid- FINAL-April-2010-Resubmission-Amended-160610. pdf [Accessed 2011 Mar 1].
72. Tandvards- och Lakemedelsformansverket Dental and Pharmaceutical Benefits Agency, TLV decides that the following drugs should be included in the reimbursement from 2010-06-30 to the table specified prices. TLV determines the alternative price to the same amount of AIP [online]. Available from URLhttp://www.tlv.se/Upload/Beslut-2010/bes100701-revlimid.pdf [Accessed 2011 Mar 2].
73. Statens legemiddelverk. Reimbursement report lenalidomide (Revlimid) to treatment of multiple myeloma: assessment of the application for pre-approved reimbursement [online]. Available from URL http://www.legemiddelverket.no/up load/Refusjonsrapport-Revlimid.pdf [Accessed 2011 Mar 8].
74. National Institute for Health and Clinical Excellence. Le- nalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy: NICE technology appraisal guidance 171 [online]. Available from URL http://www.nice.org.uk/nicemedia/pdf/TA171Gui danceWord.doc [Accessed 2010 Sep 30].
75. National Institute for Health and Clinical Excellence. Ap- praising treatments which may extend life, at the end of life [online]. Available from URL http://www.nice.org.uk/aboutnice/howwework/devnicetech/endoflifetreatments. jsp [Accessed 2010 Oct 6].
76. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Val Health 2009; 12 (4): 409-18.
77. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111 (5): 2521-6.
78. Terpos E, Sezer O, Croucher PI, et al. The use of bisphos- phonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20 (8): 1303-17.
79. Quach H, Prince HM, Mileshkin L. Treatment strategies in elderly patients with multiple myeloma: current status. Drugs Aging 2007; 24 (10): 829-50. (Pubitemid 47553792)
80. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed refractory multiple myeloma: consensus statement. Leukemia. Epub 2011 Feb 4.
81. Hayden PJ, Mitsiades CS, Anderson KC, et al. Novel therapies in myeloma. Curr Opin Hematol 2007; 14: 609-15. (Pubitemid 47494076)
82. Jain P, Gupta S, Parikh PM. New therapeutic molecules for multiple myeloma. Indian J Cancer 2008; 45 (4): 142-8.
83. Blade J, Rosinol L, Cibeira MT. Prognostic factors for mul- tiple myeloma in the era of novel agents. Ann Oncol 2008; 19 Suppl. 7: vii117-20.
84. Shah SR, Tran TM. Lenalidomide in myeloblastic syndrome and multiple myeloma. Drugs 2007; 67 (13): 1869-81. (Pubitemid 47347398)
85. Attal M, Lauwerrs V, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract no. 310]. Blood 2010; 116 (21).
86. Palumbo A, Delforge M, Catalano J, et al. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract no. 622]. Blood 2010; 116 (21).
87. McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract no. 37]. Blood 2010; 116 (21).
88. Revlimid in limbo: market slams Celgene, physicians and payers take a wait and see approach. The Pink Sheet 2010 Dec 13; 72 (50).
89. Moeremans K, Annemans L. An update: health economics of managing multiple myeloma. Eur J Cancer 2006; 42: 1684-91 (Pubitemid 44137425)